* Biochem Pharma Inc., of Laval, Quebec, said its licensee, Glaxo Wellcome plc, of London, received approval from the European Commission to market Combivir in the 15 member states of the European Union (EU). Last November, the EU's scientific advisory committee voted in favor of the drug's approval. Combivir, the first product to combine two antiretroviral drugs in a single tablet, contains Epivir (150 mg lamivudine, or 3TC) and Retrovir (300 mg zidovudine, or AZT) for HIV-infected patients.
* CellPro Inc., of Seattle, said a shareholder class action lawsuit has been filed against the company in the U.S. District Court for the Western District of Washington. The complaint alleges violations of federal and state securities laws related to CellPro's ongoing patent dispute with Baxter Healthcare Corp., of Deerfield, Ill., Beckton-Dickinson and Co., of Franklin Lakes, N.J., and Johns Hopkins University, of Baltimore. Rick Murdock, CellPro's CEO, said the shareholder allegations are without merit.
* Cel-Sci Corp., of Alexandria, Va., said two clinical sites in the U.S. have joined four Canadian sites in the ongoing clinical trial of Multikine against head and neck cancer. The two new sites are the University of South Carolina School of Medicine at Richland Memorial Hospital, in Columbia, S.C., and the Beachwood Oncology Group, in Beachwood, Ohio. Multikine is a natural mixture of cytokines, which are regulators of the immune system.
* Endorex Corp., of Lake Bluff, Ill., began a Phase II trial to evaluate its cancer drug, ImmTher, for treatment of Ewing's sarcoma, a bone cancer that afflicts children. The trial, at the University of Texas M.D. Anderson Cancer Center, in Houston, will evaluate the use of ImmTher as adjuvant therapy after surgery and intensive chemotherapy to prevent recurrence of disease in patients at high risk. ImmTher is a muramyl dipeptide immunomodulator that stimulates the patient's immune system to kill cancer cells.